ES2451790T3 - Composición para el tratamiento de la fibrosis quística - Google Patents

Composición para el tratamiento de la fibrosis quística Download PDF

Info

Publication number: ES2451790T3
Authority: ES; Spain
Prior art keywords: treprostinila; composition; cftr; cystic fibrosis; pharmaceutically acceptable
Prior art date: 2009-08-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES10739941.2T

Other languages

English (en)

Spanish (es)

Inventor

Michael Freissmuth

Xaver Koenig

Christina Gloeckel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scipharm SARL

Original Assignee

Scipharm SARL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-07

Filing date

2010-08-05

Publication date

2014-03-28

2010-08-05 Application filed by Scipharm SARL filed Critical Scipharm SARL

2014-03-28 Application granted granted Critical

2014-03-28 Publication of ES2451790T3 publication Critical patent/ES2451790T3/es

Status Active legal-status Critical Current

2030-08-05 Anticipated expiration legal-status Critical

Links

201000003883 Cystic fibrosis Diseases 0.000 title claims abstract description 33
239000000203 mixture Substances 0.000 title claims abstract description 23
150000003839 salts Chemical class 0.000 claims abstract description 24
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims abstract description 22
229960001123 epoprostenol Drugs 0.000 claims abstract description 18
229960002240 iloprost Drugs 0.000 claims abstract description 8
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims abstract description 8
229960002890 beraprost Drugs 0.000 claims abstract description 5
CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims abstract description 5
230000002265 prevention Effects 0.000 claims abstract description 5
239000002253 acid Substances 0.000 claims description 7
150000003815 prostacyclins Chemical class 0.000 claims description 5
229940002612 prodrug Drugs 0.000 claims description 4
239000000651 prodrug Substances 0.000 claims description 4
239000012730 sustained-release form Substances 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 3
230000037396 body weight Effects 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 39
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 39
210000004027 cell Anatomy 0.000 description 24
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
210000004072 lung Anatomy 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
230000004913 activation Effects 0.000 description 7
210000002472 endoplasmic reticulum Anatomy 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000000243 solution Substances 0.000 description 6
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
230000009471 action Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
210000002919 epithelial cell Anatomy 0.000 description 5
210000000981 epithelium Anatomy 0.000 description 5
230000006870 function Effects 0.000 description 5
210000003097 mucus Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000006782 ER associated degradation Effects 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
108091006335 Prostaglandin I receptors Proteins 0.000 description 4
-1 alkali metal salts Chemical class 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000000420 mucociliary effect Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
208000005069 pulmonary fibrosis Diseases 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
102000011045 Chloride Channels Human genes 0.000 description 3
108010062745 Chloride Channels Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010057190 Respiratory tract infections Diseases 0.000 description 3
239000002585 base Chemical group 0.000 description 3
210000000621 bronchi Anatomy 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010006519 Molecular Chaperones Proteins 0.000 description 2
102000005431 Molecular Chaperones Human genes 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
208000035467 Pancreatic insufficiency Diseases 0.000 description 2
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000000424 bronchial epithelial cell Anatomy 0.000 description 2
230000003491 cAMP production Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
210000004081 cilia Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
239000008103 glucose Substances 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000028161 membrane depolarization Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
229940118867 remodulin Drugs 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical compound [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 description 2
230000002792 vascular Effects 0.000 description 2
210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108091006515 Anion channels Proteins 0.000 description 1
102000037829 Anion channels Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
102000009079 Epoprostenol Receptors Human genes 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000032376 Lung infection Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
208000006038 Urogenital Abnormalities Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
206010056977 alcoholic pancreatitis Diseases 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
229960001694 anagrelide Drugs 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
206010003883 azoospermia Diseases 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229950000634 cicaprost Drugs 0.000 description 1
ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
210000003499 exocrine gland Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003174 prostaglandin I2 derivatives Chemical class 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000004878 submucosal gland Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000014616 translation Effects 0.000 description 1
PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES10739941.2T 2009-08-07 2010-08-05 Composición para el tratamiento de la fibrosis quística Active ES2451790T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09167491		2009-08-07
EP09167491		2009-08-07
PCT/EP2010/061428 WO2011015630A1 (en)	2009-08-07	2010-08-05	Composition for the treatment of cystic fibrosis

Publications (1)

Publication Number	Publication Date
ES2451790T3 true ES2451790T3 (es)	2014-03-28

Family

ID=41382119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES10739941.2T Active ES2451790T3 (es)	2009-08-07	2010-08-05	Composición para el tratamiento de la fibrosis quística

Country Status (25)

Country	Link
US (2)	US20120184622A1 (da)
EP (1)	EP2461812B1 (da)
JP (1)	JP5877787B2 (da)
KR (1)	KR101729800B1 (da)
CN (1)	CN102548559B (da)
AU (1)	AU2010280684B2 (da)
BR (1)	BR112012002578B8 (da)
CA (1)	CA2770066C (da)
CL (1)	CL2012000319A1 (da)
CY (1)	CY1114983T1 (da)
DK (1)	DK2461812T3 (da)
EA (1)	EA023720B1 (da)
ES (1)	ES2451790T3 (da)
GT (1)	GT201200038A (da)
HN (1)	HN2012000297A (da)
HR (1)	HRP20140277T1 (da)
IL (1)	IL217899B (da)
PL (1)	PL2461812T3 (da)
PT (1)	PT2461812E (da)
RS (1)	RS53234B (da)
SG (1)	SG178315A1 (da)
SI (1)	SI2461812T1 (da)
SM (1)	SMT201400057B (da)
WO (1)	WO2011015630A1 (da)
ZA (1)	ZA201200790B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
ES2693622T3 (es)	2011-01-13	2018-12-13	SciPharm S.à r.l.	Método para mejorar el injerto de células madre hematopoyéticas
SI2672957T1 (sl)	2011-02-07	2017-03-31	Scipharm Sarl	Nova sestava za zdravljenje cistične fibroze
US9505737B2 (en)	2013-01-11	2016-11-29	Corsair Pharma, Inc.	Treprostinil derivative compounds and methods of using same
ES2927844T3 (es)	2013-01-11	2022-11-11	Corsair Pharma Inc	Profármacos de treprostinil
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
SI3060041T1 (sl)	2013-10-25	2021-04-30	Insmed Incorporated	Spojine prostaciklina
EP3904326A1 (en)	2014-11-18	2021-11-03	Insmed Incorporated	Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9643911B2 (en)	2015-06-17	2017-05-09	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en)	2015-06-17	2016-07-19	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US10898494B2 (en)	2016-05-05	2021-01-26	Liquidia Technologies, Inc.	Dry powder treprostinil for the treatment of pulmonary hypertension
CA3038276A1 (en)	2016-09-26	2018-03-29	United Therapeutics Corporation	Treprostinil prodrugs
CN114072136B (zh)	2019-04-29	2024-11-29	英斯梅德股份有限公司	曲前列素前药的干粉组合物及其使用方法
WO2021041320A1 (en)	2019-08-23	2021-03-04	United Therapeutics Corporation	Treprostinil prodrugs
IL296567A (en)	2020-04-17	2022-11-01	United Therapeutics Corp	Terfostinil for use in the treatment of interstitial lung disease
US11793780B2 (en)	2020-06-09	2023-10-24	United Therapeutics Corporation	Prodrugs of treprosiinil
KR20250133451A (ko)	2020-12-14	2025-09-05	유나이티드 쎄러퓨틱스 코포레이션	트레프로스티닐 프로드러그로 질환을 치료하는 방법
AU2022229367A1 (en)	2021-03-03	2023-09-14	United Therapeutics Corporation	A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6310898A (en) *	1997-03-14	1998-10-12	Toray Industries, Inc.	Sustained-release prostaglandin i derivative preparation
US20010006979A1 (en) *	1998-07-08	2001-07-05	Richard Stratton	Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
AU2002330747B2 (en) *	2001-08-31	2007-07-19	Sucampo Ag	Prostaglandin analogs as chloride channel opener
US7550133B2 (en) *	2002-11-26	2009-06-23	Alexza Pharmaceuticals, Inc.	Respiratory drug condensation aerosols and methods of making and using them
ES2670872T3 (es) *	2003-05-22	2018-06-01	United Therapeutics Corporation	Polimorfo de una sal de dietanolamina de treprostinil
US20040265238A1 (en) *	2003-06-27	2004-12-30	Imtiaz Chaudry	Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) *	2005-01-13	2008-04-24	Greenberg Traurig LLP	Compositions for the treatment of metabolic disorders
US7893050B2 (en) *	2005-10-26	2011-02-22	Asahi Kasei Pharma Corporation	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007092343A2 (en) *	2006-02-03	2007-08-16	Scidose Llc	Novel epoprostenol formulation and method of making thereof
US20080280986A1 (en) *	2007-02-09	2008-11-13	United Therapeutics Corporation	Treprostinil treatment for interstitial lung disease and asthma

2010
- 2010-08-05 US US13/389,281 patent/US20120184622A1/en not_active Abandoned
- 2010-08-05 CN CN2010800454199A patent/CN102548559B/zh not_active Expired - Fee Related
- 2010-08-05 EP EP10739941.2A patent/EP2461812B1/en active Active
- 2010-08-05 DK DK10739941.2T patent/DK2461812T3/da active
- 2010-08-05 PL PL10739941T patent/PL2461812T3/pl unknown
- 2010-08-05 CA CA2770066A patent/CA2770066C/en not_active Expired - Fee Related
- 2010-08-05 HR HRP20140277AT patent/HRP20140277T1/hr unknown
- 2010-08-05 ES ES10739941.2T patent/ES2451790T3/es active Active
- 2010-08-05 SI SI201030560T patent/SI2461812T1/sl unknown
- 2010-08-05 KR KR1020127003535A patent/KR101729800B1/ko active Active
- 2010-08-05 EA EA201200253A patent/EA023720B1/ru not_active IP Right Cessation
- 2010-08-05 BR BR112012002578A patent/BR112012002578B8/pt not_active IP Right Cessation
- 2010-08-05 SG SG2012008702A patent/SG178315A1/en unknown
- 2010-08-05 AU AU2010280684A patent/AU2010280684B2/en not_active Ceased
- 2010-08-05 RS RS20140134A patent/RS53234B/sr unknown
- 2010-08-05 JP JP2012523343A patent/JP5877787B2/ja active Active
- 2010-08-05 PT PT107399412T patent/PT2461812E/pt unknown
- 2010-08-05 WO PCT/EP2010/061428 patent/WO2011015630A1/en not_active Ceased
2012
- 2012-02-01 ZA ZA2012/00790A patent/ZA201200790B/en unknown
- 2012-02-02 IL IL217899A patent/IL217899B/en active IP Right Grant
- 2012-02-07 CL CL2012000319A patent/CL2012000319A1/es unknown
- 2012-02-07 HN HN2012000297A patent/HN2012000297A/es unknown
- 2012-02-07 GT GT201200038A patent/GT201200038A/es unknown
2014
- 2014-03-18 CY CY20141100210T patent/CY1114983T1/el unknown
- 2014-04-29 SM SM201400057T patent/SMT201400057B/xx unknown
2015
- 2015-12-22 US US14/978,914 patent/US10086001B2/en active Active

Also Published As

Publication number	Publication date
SI2461812T1 (sl)	2014-05-30
HRP20140277T1 (hr)	2014-04-25
DK2461812T3 (da)	2014-04-07
EA023720B1 (ru)	2016-07-29
PL2461812T3 (pl)	2014-12-31
BR112012002578B1 (pt)	2021-01-12
GT201200038A (es)	2015-01-16
CN102548559A (zh)	2012-07-04
RS53234B (sr)	2014-08-29
JP2013501032A (ja)	2013-01-10
US10086001B2 (en)	2018-10-02
BR112012002578B8 (pt)	2021-05-25
US20160175319A1 (en)	2016-06-23
WO2011015630A1 (en)	2011-02-10
US20120184622A1 (en)	2012-07-19
HN2012000297A (es)	2015-05-18
EP2461812A1 (en)	2012-06-13
ZA201200790B (en)	2013-05-29
AU2010280684B2 (en)	2016-07-28
HK1165293A1 (en)	2012-10-05
KR101729800B1 (ko)	2017-04-24
CN102548559B (zh)	2013-12-25
AU2010280684A1 (en)	2012-02-23
EP2461812B1 (en)	2014-01-01
IL217899B (en)	2018-05-31
CA2770066C (en)	2018-10-23
KR20120056819A (ko)	2012-06-04
EA201200253A1 (ru)	2012-07-30
CL2012000319A1 (es)	2012-09-14
BR112012002578A2 (pt)	2016-03-15
CY1114983T1 (el)	2016-12-14
SG178315A1 (en)	2012-03-29
PT2461812E (pt)	2014-04-07
IL217899A0 (en)	2012-03-29
JP5877787B2 (ja)	2016-03-08
SMT201400057B (it)	2014-07-07
CA2770066A1 (en)	2011-02-10

Publication	Publication Date	Title
US10086001B2 (en)	2018-10-02	Composition for the treatment of cystic fibrosis
JP5997182B2 (ja)	2016-09-28	嚢胞性線維症の処置のための新規組成物
WO2012107364A1 (en)	2012-08-16	Novel composition for the treatment of cystic fibrosis
JP2011026204A (ja)	2011-02-10	タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
HK1165293B (en)	2014-04-17	Composition for the treatment of cystic fibrosis
US20080146669A1 (en)	2008-06-19	Novel Chloride Channel Pore Openers
NZ613118B2 (en)	2015-09-29	Novel composition for the treatment of cystic fibrosis
HK1187813B (en)	2017-09-29	Novel composition for the treatment of cystic fibrosis
HK1187813A (en)	2014-04-17	Novel composition for the treatment of cystic fibrosis
MXPA00008580A (en)	2001-07-31	Use of alpha-rar antagonists for inhibition of mucin secretion